The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2014Role of Parkin and Its Opponent in Parkinson’s Disease Onset
Study Rationale:
Parkin is an enzyme that adds molecules to proteins, including one called mitofusin, which bridges mitochondria (cell’s powerhouse) to the endoplasmic reticulum (structure... -
Research Grant, 2014Validation of the Movement Disorders Society’s Clinical Criteria of Parkinson’s Disease
Study Rationale:
Diagnosis of Parkinson’s disease (PD) and other causes of parkinsonism is not always an easy task for physicians. An accurate diagnosis, however, is an essential aspect of care for... -
Therapeutic Pipeline Program, 2014Restoring the Nigrostriatal Pathway with Living Micro-Tissue Engineered Axonal Tracts
Study Rationale:
By the time Parkinson’s disease (PD) symptoms appear, typically 60% of neurons in the substantia nigra and their axonal projections (nerve fibers) to the striatum... -
Rapid Response Innovation Awards, 2014Novel Mechanism for Death of Dopaminergic Neurons in a Model for Parkinson’s Disease
Study Rationale:
Parkinson’s disease (PD) is due in large part to the death of dopaminergic neurons in a part of the brain called the substantia nigra. An understanding of why, as we... -
Research Grant, 2014Novel Nicotinic Receptor Agonist for Treating Levodopa-induced Dyskinesia
Promising Outcomes of Original Grant:
Our initial hypothesis was two-fold: first, that specific nicotinic (chemical messenger) receptor subtypes are involved in nervous system responses to levodopa and... -
Research Grant, 2013Utility of a Novel Nicotinic Receptor Agonist for Treating Levodopa-induced Dyskinesia
Objective/Rationale:
It has been suggested that a nicotinic acetylcholine receptor (nAChR) agonists may restore the deficits caused by the loss of nicotinic acetylcholine subunits found in Parkinson’s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.